1
|
Madkhali MA, Alhazmi E, Hakami F, Darraj H, Hamdi S, Hakami KM, Gadi WH, Sharahily RM, Hufaysi AH, Alhazmi L, Oraibi O, Alqassimi S, Mohrag M, Elmakki E. A Cross-Sectional Study on the Knowledge and Awareness of Lung Cancer and Screening in Jazan Region, Saudi Arabia. J Multidiscip Healthc 2023; 16:3857-3870. [PMID: 38076592 PMCID: PMC10710187 DOI: 10.2147/jmdh.s435129] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Accepted: 11/28/2023] [Indexed: 12/30/2023] Open
Abstract
BACKGROUND Lung cancer (LC) is the most common cause of cancer-related deaths worldwide. With lung cancer often diagnosed at advanced stages, understanding the local population's awareness levels is crucial for designing effective preventive strategies. By identifying gaps in knowledge, the research aims to inform targeted health education efforts, optimize resource allocation, influence policy development, and contribute to the limited body of research on lung cancer awareness in the region, ultimately fostering improved public health outcomes. METHODS This was a cross-sectional observational study conducted in Jazan region, Saudi Arabia, from July 2022 to June 2023, 671 participants over 18 years old, encompassing both genders, were gsurveyed. Data was collected through a questionnaire covering sociodemographic characteristics and LC-related awareness. SPSS 23 was used for analysis. Factors associated with knowledge scores were explored using independent t-tests and ANOVA, with the Tukey post-hoc test identifying specific group differences. RESULTS The study included 671 participants, most participants were between 18 and 35 years (73.5%), with 38.5% males and 61.5% females. Lung cancer (LC) awareness was high (95.1%), with 4.9% reporting a family history. Knowledge assessment revealed a mean score of 14.66, with 41.6% having low, 49.5% moderate, and 8.9% high knowledge levels. Correct responses were notable for recognizing LC as a common cancer, a leading cause of death, and associating smoking and shisha with risk. Symptoms were well identified. Screening awareness was at 63.5%, with 78.8% willing to undergo tests if at risk. Age, marital status, and occupation were associated with knowledge, while factors like gender, nationality, residency, education, income, and smoking status showed no significant associations. CONCLUSION The findings indicate that there are knowledge gaps related to LC and its screening in Jazan region in Saudi Arabia. Effective awareness programs targeting specific sociodemographic groups are needed to improve the early detection and outcomes.
Collapse
Affiliation(s)
- Mohammed Ali Madkhali
- Department of Internal Medicine, Division of Hematology and Oncology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Essam Alhazmi
- Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Faisal Hakami
- Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Hussam Darraj
- Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Sulaiman Hamdi
- Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | | | - Wala H Gadi
- Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | | | | | - Luai Alhazmi
- Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Omar Oraibi
- Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Sameer Alqassimi
- Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Mostafa Mohrag
- Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| | - Erwa Elmakki
- Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
| |
Collapse
|
2
|
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S. Association between lung cancer somatic mutations and occupational exposure in never-smokers. Eur Respir J 2017; 50:50/4/1700716. [PMID: 29074543 DOI: 10.1183/13993003.00716-2017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 08/03/2017] [Indexed: 01/06/2023]
Abstract
Occupational exposure constitutes a common risk factor for lung cancer. We observed molecular alterations in 73% of never-smokers, 35% of men and 8% of women were exposed to at least one occupational carcinogen. We report herein associations between molecular patterns and occupational exposure.BioCAST was a cohort study of lung cancer in never-smokers that reported risk factor exposure and molecular patterns. Occupational exposure was assessed via a validated 71-item questionnaire. Patients were categorised into groups that were unexposed and exposed to polycyclic aromatic hydrocarbons (PAH), asbestos, silica, diesel exhaust fumes (DEF), chrome and paints. Test results were recorded for EGFR, KRAS, HER2, BRAF and PIK3 mutations, and ALK alterations.Overall, 313 out of 384 patients included in BioCAST were analysed. Asbestos-exposed patients displayed a significantly lower rate of EGFR mutations (20% versus 44%, p=0.033), and a higher rate of HER2 mutations (18% versus 4%, p=0.084). ALK alterations were not associated with any occupational carcinogens. The DEF-exposed patients were diagnosed with a BRAF mutation in 25% of all cases. Chrome-exposed patients exhibited enhanced HER2 and PIK3 mutation frequency.Given its minimal effects in the subgroups, we conclude that occupational exposure slightly affects the molecular pattern of lung cancers in never-smokers. In particular, asbestos-exposed patients have a lower chance of EGFR mutations.
Collapse
Affiliation(s)
- Christophe Paris
- Equipe ESTER, centre INSERM U1085 IRSET, Rennes, France.,Service de maladies professionnelles, Hôpital Pontchaillou, CHU de Rennes, Rennes, France
| | - Pascal Do
- UCP d'oncologie thoracique, Centre de lutte contre le cancer François Baclesse, Caen, France
| | - Bénédicte Mastroianni
- Service de pneumologie, Institut de cancérologie des Hospices Civils de Lyon, Hôpital Louis Pradel, Bron, France
| | - Adrien Dixmier
- Service de pneumologie et oncologie thoracique, Centre hospitalier régional d'Orléans, Orléans, France
| | - Patrick Dumont
- Service de pneumologie, Centre Hospitalier de Chauny, Chauny, France
| | - Eric Pichon
- Service de pneumologie, CHRU de Tours, Hôpital Bretonneau, Tours, France
| | - Christos Chouaid
- OncoThoParisEst, Service de pneumologie, CHI Créteil, UPEC, Créteil, France
| | - Bruno Coudert
- Oncologie Médicale, Centre GF Leclerc, Dijon, France
| | - Pascal Foucher
- Fédération d'Oncologie Thoracique, CHU Dijon-Bourgogne, Hôpital du Bocage, Dijon, France
| | | | - Myriam Locatelli-Sanchez
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, Institut de cancérologie des Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France
| | - Nathalie Baize
- Unité Transversale de Thérapeutiques Innovantes en Oncologie Médicale (UTTIOM), CHU d'Angers, Angers, France
| | - Eric Dansin
- Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
| | | | - Michel Vincent
- Service de pneumologie et cancérologie thoracique Centre Hospitalier Saint Joseph et Saint Luc, Lyon, France.,Minapath Développement Insavalor, Villeurbanne, France
| | - Pascale Missy
- Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France
| | - Franck Morin
- Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France
| | - Denis Moro-Sibilot
- Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France.,Clinique de pneumologie et oncologie thoracique, CHU Grenoble-Alpes, La Tronche, France
| | - Sébastien Couraud
- Service de pneumologie aiguë spécialisée et cancérologie thoracique, Institut de cancérologie des Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France .,EMR 3738 Ciblage thérapeutique en oncologie, Faculté de médecine Lyon Sud, Université Lyon 1, Oullins, France
| | | | | |
Collapse
|
3
|
Dahl E, Kloten V. [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations]. DER PATHOLOGE 2016; 36:572-8. [PMID: 26395890 DOI: 10.1007/s00292-015-0078-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Molecular biological analysis of nucleic acids in blood or other bodily fluids (i.e. liquid biopsy analyses) may supplement the pathologists' diagnostic armamentarium in a reasonable way-particularly in cancer precision medicine. Within the field of oncology, liquid biopsy can potentially be used to monitor tumor burden in the blood and to early detect emerging resistance in the course of targeted cancer therapies. An already approved application of liquid biopsy is the detection of epidermal growth factor receptor (EGFR) driver mutations in blood samples of lung cancer patients in those cases where no tissue biopsy is available. However, there is still currently considerable insecurity associated with blood-based DNA analytic methods that must be solved before liquid biopsy can be implemented for broader routine application in the diagnosis of cancer. In this article, the current state of development of liquid biopsy in molecular diagnostics from a pathology point of view is presented.
Collapse
Affiliation(s)
- E Dahl
- Arbeitsgruppe Molekulare Onkologie, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. .,Molekularpathologische Diagnostik, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. .,RWTH zentralisierte Biomaterialbank (RWTH cBMB), Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.
| | - V Kloten
- Arbeitsgruppe Molekulare Onkologie, Institut für Pathologie, Uniklinik RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland.
| |
Collapse
|
4
|
Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ. No impact of passive smoke on the somatic profile of lung cancers in never-smokers. Eur Respir J 2015; 45:1415-25. [DOI: 10.1183/09031936.00097314] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 11/10/2014] [Indexed: 11/05/2022]
Abstract
EGFR and HER2 mutations and ALK rearrangement are known to be related to lung cancer in never-smokers, while KRAS, BRAF and PIK3CA mutations are typically observed among smokers. There is still debate surrounding whether never-smokers exposed to passive smoke exhibit a “smoker-like” somatic profile compared with unexposed never-smokers.Passive smoke exposure was assessed in the French BioCAST/IFCT-1002 never-smoker lung cancer cohort and routine molecular profiles analyses were compiled.Of the 384 patients recruited into BioCAST, 319 were tested for at least one biomarker and provided data relating to passive smoking. Overall, 219 (66%) reported having been exposed to passive smoking. No significant difference was observed between mutation frequency and passive smoke exposure (EGFR mutation: 46% in never exposed versus 41% in ever exposed; KRAS: 7% versus 7%; ALK: 13% versus 11%; HER2: 4% versus 5%; BRAF: 6% versus 5%; PIK3CA: 4% versus 2%). We observed a nonsignificant trend for a negative association between EGFR mutation and cumulative duration of passive smoke exposure. No association was found for other biomarkers.There is no clear association between passive smoke exposure and somatic profile in lifelong, never-smoker lung cancer.
Collapse
|
5
|
Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J 2015; 45:1403-14. [DOI: 10.1183/09031936.00097214] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 11/23/2014] [Indexed: 12/14/2022]
Abstract
Lung cancer in never-smokers (LCINS) (fewer than 100 cigarettes in lifetime) is considered as a distinct entity and harbours an original molecular profile. However, the epidemiological and molecular features of LCINS in Europe remain poorly understood.All consecutive newly diagnosed LCINS patients were included in this prospective observational study by 75 participating centres during a 14-month period. Each patient completed a detailed questionnaire about risk factor exposure. Biomarker and pathological analyses were also collected. We report the main descriptive overall results with a focus on sex differences.384 patients were included: 65 men and 319 women. 66% had been exposed to passive smoking (significantly higher among women). Definite exposure to main occupational carcinogens was significantly higher in men (35%versus8% in women). A targetable molecular alteration was found in 73% of patients (without any significant sex difference):EGFRin 51%,ALKin 8%,KRASin 6%,HER2in 3%,BRAFin 3%,PI3KCAin less than 1%, and multiple in 2%.We present the largest and most comprehensive LCINS analysis in a European population. Physicians should track occupational exposure in men (35%), and a somatic molecular alteration in both sexes (73%).
Collapse
|
6
|
Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 2014; 20:4613-24. [PMID: 25013125 DOI: 10.1158/1078-0432.ccr-13-3063] [Citation(s) in RCA: 178] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Tumor somatic mutation analysis is part of the standard management of metastatic lung cancer. However, physicians often have to deal with small biopsies and consequently with challenging mutation testing. Circulating free DNA (cfDNA) is a promising tool for accessing the tumor genome as a liquid biopsy. Here, we evaluated next-generation sequencing (NGS) on cfDNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations. EXPERIMENTAL DESIGN A total of 107 plasma samples were collected from the BioCAST/IFCT-1002 lung cancer study (never-smokers cohort). Matched tumor DNA (tDNA) was obtained for 68 cases. Multiplex PCR-based assays were designed to target specific coding regions in EGFR, KRAS, BRAF, ERBB2, and PI3KCA genes, and amplicon sequencing was performed at deep coverage on the cfDNA/tDNA pairs using the NGS IonTorrent Personal Genome Machine Platform. RESULTS CfDNA concentration in plasma was significantly associated with both stage and number of metastatic sites. In tDNA, 50 mutations (36 EGFR, 5 ERBB2, 4 KRAS, 3 BRAF, and 2 PIK3CA) were identified, of which 26 were detected in cfDNA. Sensitivity of the test was 58% (95% confidence interval, 43%-71%) and the estimated specificity was 87% (62%-96%). CONCLUSION These data demonstrate the feasibility and potential utility of mutation screening in cfDNA using IonTorrent NGS for the detection of a range of tumor biomarkers in patients with metastatic lung cancer.
Collapse
Affiliation(s)
- Sébastien Couraud
- International Agency for Research on Cancer, Section of Mechanisms of Carcinogenesis, Molecular Mechanisms and Biomarkers Group, Lyon Cedex, France. Department of Pulmonology, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France. Lyon Sud Faculty of Medicine, Lyon 1 University, Pierre Bénite Cedex, France.
| | - Felipe Vaca-Paniagua
- International Agency for Research on Cancer, Section of Mechanisms of Carcinogenesis, Molecular Mechanisms and Biomarkers Group, Lyon Cedex, France. Laboratorio de Genómica, Instituto Nacional de Cancerología, Tlalpan, México. Unidad de Biomedicina, FES-Iztacala, UNAM, México
| | - Stéphanie Villar
- International Agency for Research on Cancer, Section of Mechanisms of Carcinogenesis, Molecular Mechanisms and Biomarkers Group, Lyon Cedex, France
| | - Javier Oliver
- International Agency for Research on Cancer, Genetic Cancer Susceptibility Group, Lyon Cedex, France
| | - Tibor Schuster
- Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada
| | | | - Nicolas Girard
- Department of Respiratory Medicine, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France. Claude Bernard University Lyon 1, Lyon (Bron), France
| | - Jean Trédaniel
- Department of Pulmonology, Paris - Saint Joseph Hospital, and Sorbonne Paris Cité university, France
| | - Laurent Guilleminault
- Pulmonology Unit, University Hospital of Tours, France and François Rabelais University, Respiratory Diseases Study Centre, Tours, France
| | - Radj Gervais
- Francois Baclesse Cancer Institute, Caen, France
| | - Nathalie Prim
- Department of Chest, Strasbourg University Hospital, Strasbourg, France
| | - Michel Vincent
- Department of Pulmonology, Saint Joseph-Saint Luc Hospital, Lyon, France
| | - Jacques Margery
- Department of Respiratory Department, Percy Military Hospital, Clamart, France
| | | | - Pascal Foucher
- Thoracic Oncology, Dijon University Hospital, Dijon, France
| | - Bernard Duvert
- Department of Oncology, Montélimar Hospital, Montélimar, France
| | - Maxime Vallee
- International Agency for Research on Cancer, Genetic Cancer Susceptibility Group, Lyon Cedex, France
| | - Florence Le Calvez-Kelm
- International Agency for Research on Cancer, Genetic Cancer Susceptibility Group, Lyon Cedex, France
| | - James McKay
- International Agency for Research on Cancer, Genetic Cancer Susceptibility Group, Lyon Cedex, France
| | - Pascale Missy
- Intergroupe Francophone de Cancérologie Thoracique, Paris, France
| | - Franck Morin
- Intergroupe Francophone de Cancérologie Thoracique, Paris, France
| | - Gérard Zalcman
- Pulmonology and Thoracic Oncology Unit and UMR 1086 Inserm "Cancers and Préventions," Caen University Hospital, Caen, France
| | - Magali Olivier
- International Agency for Research on Cancer, Section of Mechanisms of Carcinogenesis, Molecular Mechanisms and Biomarkers Group, Lyon Cedex, France
| | - Pierre-Jean Souquet
- Department of Pulmonology, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France. Lyon Sud Faculty of Medicine, Lyon 1 University, Pierre Bénite Cedex, France
| |
Collapse
|